Question 1

What is Alnylam Pharmaceuticals's EV/EBITDA ratio?

Accepted Answer

Alnylam Pharmaceuticals (ALNY) EV/EBITDA ratio is 38.0× as of July 22, 2026. The ratio is calculated by dividing enterprise value by trailing twelve-month EBITDA, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the EV/EBITDA ratio calculated?

Accepted Answer

EV/EBITDA = Enterprise Value ÷ Trailing Twelve-Month (TTM) EBITDA, where Enterprise Value = Market Capitalisation + Total Debt − Cash & Short-Term Investments. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the EV/EBITDA ratio?

Accepted Answer

The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.

Question 4

What is a good EV/EBITDA ratio for Alnylam Pharmaceuticals?

Accepted Answer

Mature, cash-generative businesses commonly trade in the 8–12× EV/EBITDA range; higher-growth, asset-light companies often trade at 15–25×+. EV/EBITDA is most useful for comparing companies with different capital structures (debt levels) or tax regimes. For Alnylam Pharmaceuticals specifically, the relevant sector benchmark is the current sector median of 14.2×.

Question 5

Is Alnylam Pharmaceuticals's EV/EBITDA ratio high or low?

Accepted Answer

Alnylam Pharmaceuticals's EV/EBITDA ratio of 38.0× is below its own 5-year average of 172.2× and above the sector median of 14.2×. That places the current reading at the 0th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Alnylam Pharmaceuticals's historical EV/EBITDA ratio range?

Accepted Answer

In the available daily series, Alnylam Pharmaceuticals (ALNY) EV/EBITDA ratio has ranged from a low of 38.0× in 2026 to a high of 340.9× in 2025. The 5-year average is 172.2× and the 5-year median is 164.7×.

Question 7

What was Alnylam Pharmaceuticals's EV/EBITDA ratio in 2025?

Accepted Answer

Alnylam Pharmaceuticals (ALNY) EV/EBITDA ratio at the end of 2025 was 80.7×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month EBITDA figure available at that date.

Question 8

Why does Alnylam Pharmaceuticals's EV/EBITDA ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (enterprise value, which tracks share price plus net debt) and the denominator (EBITDA). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$52.6B	$631M	80.7×	—	Dec 31, 2025
2024	$30.3B	-$179M	—	—	Dec 31, 2024
2023	$24B	-$258M	—	—	Dec 31, 2023
2022	$29.3B	-$927M	—	—	Dec 31, 2022
2021	$20.3B	-$662M	—	—	Dec 31, 2021
2020	$15.1B	-$736M	—	—	Dec 31, 2020
2019	$12.9B	-$862M	—	—	Dec 31, 2019
2018	$7.37B	-$809M	—	—	Dec 31, 2018
2017	$12.2B	-$487M	—	—	Dec 31, 2017
2016	$3.21B	-$409M	—	—	Dec 31, 2016
2015	$7.99B	-$277M	—	—	Dec 31, 2015
2014	$7.46B	-$172M	—	—	Dec 31, 2014
2013	$4.05B	-$82.7M	—	—	Dec 31, 2013
2012	$946M	-$55.6M	—	—	Dec 31, 2012
2011	$377M	-$49.7M	—	—	Dec 31, 2011
2010	$416M	-$41M	—	—	Dec 31, 2010
2009	$738M	-$42.3M	—	—	Dec 31, 2009
2008	$1.02B	-$18.9M	—	—	Dec 31, 2008
2007	$1.18B	-$89.1M	—	—	Dec 31, 2007
2006	$800M	-$36.5M	—	—	Dec 31, 2006
2005	$401M	-$40.4M	—	—	Dec 31, 2005
2004	$153M	-$29.8M	—	—	Dec 31, 2004
2003	$9.95M	-$23.6M	—	—	Dec 31, 2003


Gilead Sciences (GILD)	13.2×
Becton, Dickinson and (BDX)	12.9×
Regeneron Pharmaceuticals (REGN)	12.9×
Medtronic (MDT)	12.9×
STERIS (STE)	12.8×
Pfizer (PFE)	12.5×
Align Technology (ALGN)	12.4×
IQVIA (IQV)	12.2×
GE HealthCare (GEHC)	12.0×
Henry Schein (HSIC)	11.9×
Bristol-Myers Squibb (BMY)	11.5×
Zimmer Biomet Holdings (ZBH)	11.2×
AptarGroup (ATR)	11.1×
Viatris (VTRS)	11.0×
Biogen (BIIB)	10.8×
HCA Healthcare (HCA)	10.0×
Elevance Health (ELV)	9.7×
AstraZeneca (AZN)	8.7×
DaVita (DVA)	8.5×
Incyte (INCY)	7.9×
Cigna (CI)	7.6×
Novo Nordisk (NVO)	6.3×
Solventum (SOLV)	5.8×
Universal Health Services (UHS)	5.7×
Humana (HUM)	4.5×

EV/EBITDA for Alnylam Pharmaceuticals (ALNY) 2025-2026

EV/EBITDA daily chart for Alnylam Pharmaceuticals (ALNY)

Historical EV/EBITDA for Alnylam Pharmaceuticals (ALNY) from 2003 to 2025

About EV/EBITDA at Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals EV/EBITDA by Year

Alnylam Pharmaceuticals EV/EBITDA 2025: 80.7×

Sector peers by EV/EBITDA — chart

Sector peers by EV/EBITDA — table

Frequently asked questions

Alnylam Pharmaceuticals (ALNY) Key Financials